Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session. This move lagged the S&P 500’s daily gain of 1.39%. At the same time, the Dow added 1.11%, and the tech-heavy Nasdaq gained 1.65%.

Heading into today, shares of the company had gained 51.24% over the past month, outpacing the Medical sector’s gain of 29.23% and the S&P 500’s gain of 25.31% in that time.

Investors will be hoping for strength from SMMT as it approaches its next earnings release. The company is expected to report EPS of -$0.11, up 68.57% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.79 million, up 170.61% from the year-ago